Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. - Wikidata - wikimedia - TriplyDB

Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy.

Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy.

http://www.wikidata.org/entity/Q43013288

about

Fusarium and Candida albicans biofilms on soft contact lenses: model development, influence of lens type, and susceptibility to lens care solutions Anti-Immune Strategies of Pathogenic Fungi The Cryptococcus neoformans capsule: lessons from the use of optical tweezers and other biophysical tools Antibody-mediated immobilization of Cryptococcus neoformans promotes biofilm formation.Antibody binding to Cryptococcus neoformans impairs budding by altering capsular mechanical properties.Pathogenesis of mucosal biofilm infections: challenges and progress.Antigenic and phenotypic variations in fungi Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism.Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro Antibody-guided alpha radiation effectively damages fungal biofilms Medical biofilms.Biofilm formation by Cryptococcus neoformans under distinct environmental conditions.Cryptococcus neoformans cells in biofilms are less susceptible than planktonic cells to antimicrobial molecules produced by the innate immune system.Cryptococcus neoformans biofilm formation depends on surface support and carbon source and reduces fungal cell susceptibility to heat, cold, and UV light Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models.The Anti-helminthic Compound Mebendazole Has Multiple Antifungal Effects against Cryptococcus neoformans.Magnesium Ion Acts as a Signal for Capsule Induction in Cryptococcus neoformans.Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine.Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.Methamphetamine enhances Cryptococcus neoformans pulmonary infection and dissemination to the brain.Cryptococcus neoformans constitutes an ideal model organism to unravel the contribution of cellular aging to the virulence of chronic infections.The use of chitosan to damage Cryptococcus neoformans biofilms.Quorum sensing-mediated, cell density-dependent regulation of growth and virulence in Cryptococcus neoformans.Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responses Our current understanding of fungal biofilms.Pertussis: a matter of immune modulation.Fungal Biofilms: Relevance in the Setting of Human Disease.Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.Candida species: new insights into biofilm formation.Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment.Cryptococcus antigens and immune responses: implications for a vaccine.Innate host defenses against Cryptococcus neoformans.The Extracellular Matrix of Fungal Biofilms.Virulence of Cryptococcus sp. Biofilms In Vitro and In Vivo using Galleria mellonella as an Alternative Model Biofilm localization in the vertical wall of shaking 96-well plates.Role of a VPS41 homologue in starvation response, intracellular survival and virulence of Cryptococcus neoformans.EDTA inhibits biofilm formation, extracellular vesicular secretion, and shedding of the capsular polysaccharide glucuronoxylomannan by Cryptococcus neoformans.Vesicular transport across the fungal cell wall.Use of a stainless steel washer platform to study Acinetobacter baumannii adhesion and biofilm formation on abiotic surfaces.Characterization of phenotypic switching in Cryptococcus neoformans biofilms.

P2860

Q24657601-4A934CD5-CABC-45F6-BBCF-B7D4FE44600C Q28071716-35F0B13E-E874-4143-AF2D-C1A409C2AF3C Q28087622-C2514E64-996B-4180-A7C0-7458CD4F9CD3 Q30487314-AA965169-3588-4DE8-B766-E205BAB43360 Q30530667-F331A8D1-22AB-483A-AF5B-144459662ECB Q33326460-5FD85A5D-3D52-42BC-9A26-A4A7F822AC1F Q33505448-7F15D3BA-F8D3-4741-BE1D-C4EEE36D5103 Q33755308-8885D1FF-3FA0-495C-8826-CDF1A4CCA8E0 Q34509773-850F47E0-2889-4324-99CA-6EDDC166F4E2 Q34680558-703FB3E4-EDDF-452C-83A1-52D5BCAB467F Q34764576-0892A747-582E-4A70-AA52-031ECC3E5783 Q34781743-18BB4CB3-0DCB-477F-9A6B-9FE6C64DCDA4 Q35217511-F0E9D269-50C7-471B-AE28-31FB5C80DF72 Q35913297-05E07FB8-04B5-415B-83A8-97A3C7FF732A Q36192774-B9D60049-8325-4DB5-931B-BF853E572841 Q36344094-D99ED87B-57FC-487B-BF53-A49AF8403368 Q36686273-04628B8C-D5F8-42D3-B307-2E07F42CC837 Q36690302-E5C97F9A-E85D-4687-8DD6-F63EBBD7C516 Q36914682-64C45582-0B99-4C5B-ADFC-407D9802BB33 Q37074706-132604E3-13BB-431F-921B-D382CEC8F7B7 Q37126044-F28FABAB-5D42-424B-9A86-1E65782CA95B Q37438897-E83C82AC-B076-48D7-8AD5-1C0E1B136ABB Q37446469-36257E71-E586-4001-8C6C-7651D24A07CC Q37562226-0C43F04F-22E9-4907-AB58-3069EDAB1DA1 Q37622959-3B0D6C43-B8E7-4748-8C1A-3616A7481E2A Q37825920-099CBB2E-0DF7-468E-8028-AA03F9B1238F Q37887512-5507C819-73F4-4EFB-BB6F-E6785380AFCE Q38011299-75321AA3-2F01-4E84-A284-3292B4D238EC Q38019018-5D17687B-C486-4520-A7A8-CF17C8A33330 Q38154164-C450F186-C06D-40C0-A95B-37516269A1BF Q38155197-E5039E80-CF20-450B-8D2D-1ADC787C3E2D Q38752388-81B82420-F5C9-4239-BC59-E3FCEC816789 Q38856993-D8962229-FC44-48B3-B344-590CF7C9A6F6 Q38858709-FDD76983-A0A0-44D9-897D-4C858750ABB0 Q39192972-C9CFC4AA-4DCD-4EE8-A5D2-F4D3BDDADC15 Q40249599-2FFAEA04-3A59-42F0-9666-C07AAD80F11C Q41588074-0E9A8C2A-880E-49CF-B1FD-7C030E32D42A Q41825169-4B11CFE2-8AF2-4374-8D06-EF55191CC35C Q42248142-9C05D0FC-C350-469A-BF17-95CCE134CC00 Q43077543-D4B126A5-6319-4034-850B-BA092397C3DD

P2860

Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy.

http://www.wikidata.org/entity/Q43013288

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Specific antibody can prevent ...... ates with protective efficacy.

@en

Specific antibody can prevent ...... ates with protective efficacy.

@nl

type

label

Specific antibody can prevent ...... ates with protective efficacy.

@en

Specific antibody can prevent ...... ates with protective efficacy.

@nl

prefLabel

Specific antibody can prevent ...... ates with protective efficacy.

@en

Specific antibody can prevent ...... ates with protective efficacy.

@nl

P1433

Q43013288-7100BDCF-312F-491C-BE71-6968BCC99676

P1476

Q43013288-47A2BE41-DDD0-43F3-A686-64F524AB8F53

P2093

Q43013288-17FB44AA-6898-4281-A375-06DB263BA6F1

P2860

Q43013288-026E7D6B-E09B-48CA-95C1-57924CC82C3F

Q43013288-03FACE27-0C54-4B1D-AC31-364CDCD309F7

Q43013288-086D50A8-D4D9-4130-9237-04D99DB37F3C

Q43013288-0FE6CA29-2AFA-41A2-B213-E6955A68F54F

Q43013288-10654C1F-87CC-41FC-B45D-CBD5A71F9911

Q43013288-11CF64D9-1040-47F7-AA3D-87099DC72A02

Q43013288-1862F888-89D8-4E1E-ACED-66FFCCAF5A7F

Q43013288-206D8224-30F9-417D-83A9-1A2455BF714F

Q43013288-2294A36A-D82F-4132-8B00-6DD3B34612A7

Q43013288-280C7579-DAD0-4E9B-A1B1-808BC755E6C9

P304

Q43013288-676D320A-F244-4E45-9EC1-FDAE85C4E353

P31

Q43013288-020F9D99-B23E-43D7-9DD6-3ED78465EFB7

P356

Q43013288-9144235D-7FEA-49BD-BDFE-EE474869513B

P407

Q43013288-F4E80ADC-B69A-4111-9AC9-115BB1D5167E

P433

Q43013288-107FAFA4-9ED0-44A8-B02F-38388E9CCC4B

P478

Q43013288-D8622906-6394-4702-A694-1299E0B249C2

P50

Q43013288-960424B6-E7FA-4194-AEF8-D786B231B8EA

P577

Q43013288-4634C026-7C52-46D6-B387-91C54BDC480C

P698

Q43013288-F2AC1071-6466-4E26-BB2D-B8AF7B6374B4

P921

Q43013288-40932D58-BD10-48D7-88D5-28C80B5A531C

Q43013288-AF8E2FB2-553E-4206-9D25-14221A4FF1E9

P932

Q43013288-40C37C3F-00D6-46AD-A1A0-C67479766D11

P356

IAI.73.10.6350-6362.2005

P1433

Infection and Immunity

P1476

Specific antibody can prevent ...... ates with protective efficacy.

@en

P2093

Luis R Martinez

http://www.w3.org/2001/XMLSchema#string

P2860

Biofilms: microbial life on surfaces

A component of innate immunity prevents bacterial biofilm development

Glucuronoxylomannan, a microbial compound, regulates expression of costimulatory molecules and production of cytokines in macrophages

Bacterial biofilms: from the natural environment to infectious diseases

Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance

Role of alginate and its O acetylation in formation of Pseudomonas aeruginosa microcolonies and biofilms.

Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule

Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.

P304

6350-6362

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.73.10.6350-6362.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P50

Arturo Casadevall

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16177306

http://www.w3.org/2001/XMLSchema#string

P921

P932

1230912

http://www.w3.org/2001/XMLSchema#string